Price Chart

Executive Summary

Nutriband Inc. announced the selection of a commercial worldwide brand name for its lead product, an abuse-deterrent fentanyl transdermal patch, which will be submitted to the FDA and other regulatory agencies for approval. The company partnered with Brand Institute, a leader in pharmaceutical naming, to develop the brand and ensure compliance with global safety standards.

Key Facts

• Nutriband selected a commercial brand name for its abuse-deterrent fentanyl transdermal system for global use.
• The name and labeling will be submitted to the FDA and international regulators for approval.
• Brand Institute, a global leader in pharmaceutical naming, was engaged to develop the brand and visual identity.
• Drug Safety Institute, a subsidiary of Brand Institute, will provide regulatory support.
• The product leverages Nutriband’s AVERSA™ technology and targets peak annual U.S. sales of $80M–$200M.

Financial Impact

No immediate financial impact; potential future revenue estimated at $80M–$200M in peak annual U.S. sales

Risk Factors

• Regulatory rejection of the proposed brand name due to sound-alike or look-alike concerns
• Delays or failure in FDA approval of the product itself, regardless of brand name status
• Forward-looking sales estimates may not materialize due to market competition or adoption

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status